Product Description: Elinzanetant-d3 (NT-814-d3) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women[1][2][3].
Applications: Neuroscience-Neuromodulation
Formula: C33H32D3F7N4O3
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216./[2]Alvaro, Giuseppe; Andreotti, Daniele; Belvedere, Sandro; Di Fabio, Romano; Falchi, Alessandro; Giovannini, Riccardo.Pyridine derivatives as NK receptor inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of psychotic disorders.CN101305011B/[3]Steve Pawsey, et al. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234./[4]Simon JA, et al. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1). Menopause. 2023 Mar 1;30(3):239-246.
Molecular Weight: 671.66
Research Area: Neurological Disease;Cardiovascular Disease
Target: Isotope-Labeled Compounds;Neurokinin Receptor
Deutsch
English
